Sign Out
Pharmacotherapeutic Group: Antiplatelet Agent; Phosphodiesterase Enzyme Inhibitor.
Pharmacology: Pharmacodynamics: Mechanism of Action: Cilostazol and its metabolites are inhibitors of phosphodiesterase III. As a result cyclic AMP is increased leading to inhibition of platelet aggregation, vasodilation and inhibition of platelet aggregation, vasodilation, and inhibition of vascular smooth muscle cell proliferation.
Pharmacodynamics/kinetics: Onset of action: 2-4 weeks; may require up to 12 weeks.
Protein binding: Cilostazol 95% to 98%; active metabolites 66% to 97%.
Metabolism: Hepatic via CYP3A4 (primarily), 1A2, 2C19, and 2D6; at least one metabolite has significant activity.
Half-life elimination: 11-13 hours.
Excretion: Urine (74%) and (20%) as metabolites.
Continue with Google